A phase I clinical trial to evaluate the safety and immunogenicity of a recombinant multiclade HIV-1 adenoviral vector vaccine, VRC-HIVADV014-00-VP, in uninfected adult volunteers
Latest Information Update: 31 Jan 2017
Price :
$35 *
At a glance
- Drugs VRC-HIVADV014-00-VP (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 31 Oct 2005 New trial record.